Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003823844 | SCV004624391 | uncertain significance | Luscan-Lumish syndrome | 2023-09-19 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with SETD2-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces lysine, which is basic and polar, with glutamic acid, which is acidic and polar, at codon 1191 of the SETD2 protein (p.Lys1191Glu). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt SETD2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004953567 | SCV005495690 | uncertain significance | Inborn genetic diseases | 2024-12-09 | criteria provided, single submitter | clinical testing | The c.3571A>G (p.K1191E) alteration is located in exon 3 (coding exon 3) of the SETD2 gene. This alteration results from a A to G substitution at nucleotide position 3571, causing the lysine (K) at amino acid position 1191 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |